vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Strive, Inc. (ASST). Click either name above to swap in a different company.
Strive, Inc. is the larger business by last-quarter revenue ($255.0K vs $169.0K, roughly 1.5× Aligos Therapeutics, Inc.). On growth, Aligos Therapeutics, Inc. posted the faster year-over-year revenue change (-72.1% vs -74.1%). Over the past eight quarters, Strive, Inc.'s revenue compounded faster (77.6% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Strive Asset Management is an American investment management firm founded in 2022. The firm operates mutual funds, exchange-traded products (ETPs), and wealth management services. Headquartered in Columbus, Ohio, it operates as a subsidiary of Strive Enterprises, Inc. and is registered with the U.S. Securities and Exchange Commission (SEC) as an investment adviser.
ALGS vs ASST — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $255.0K |
| Net Profit | — | $-192.3M |
| Gross Margin | — | — |
| Operating Margin | — | -17288.6% |
| Net Margin | — | -75406.7% |
| Revenue YoY | -72.1% | -74.1% |
| Net Profit YoY | 75.8% | -2726.9% |
| EPS (diluted) | — | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | — | ||
| Q3 25 | $741.0K | $255.0K | ||
| Q2 25 | $965.0K | $173.3K | ||
| Q1 25 | $311.0K | $170.7K | ||
| Q4 24 | $606.0K | $212.8K | ||
| Q3 24 | $1.3M | $984.0K | ||
| Q2 24 | $1.1M | $93.0K | ||
| Q1 24 | $694.0K | $124.8K |
| Q4 25 | — | — | ||
| Q3 25 | $-31.5M | $-192.3M | ||
| Q2 25 | $-15.9M | $-8.9M | ||
| Q1 25 | $43.1M | $-3.7M | ||
| Q4 24 | $-82.2M | $-4.1M | ||
| Q3 24 | $-19.3M | $-6.8M | ||
| Q2 24 | $5.1M | $-5.9M | ||
| Q1 24 | $-34.9M | $-4.8M |
| Q4 25 | — | — | ||
| Q3 25 | -3827.4% | -17288.6% | ||
| Q2 25 | -1924.0% | -1553.9% | ||
| Q1 25 | -6187.5% | -970.5% | ||
| Q4 24 | -3393.2% | -5889.5% | ||
| Q3 24 | -1610.5% | -712.4% | ||
| Q2 24 | -2489.5% | -1857.2% | ||
| Q1 24 | -3176.7% | -1110.9% |
| Q4 25 | — | — | ||
| Q3 25 | -4256.0% | -75406.7% | ||
| Q2 25 | -1643.8% | -5122.4% | ||
| Q1 25 | 13854.7% | -2195.6% | ||
| Q4 24 | -13556.1% | -1935.5% | ||
| Q3 24 | -1540.7% | -691.3% | ||
| Q2 24 | 477.0% | -6313.1% | ||
| Q1 24 | -5023.5% | -3837.7% |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | $-0.22 | ||
| Q2 25 | $-1.53 | $-0.17 | ||
| Q1 25 | $-2.11 | $-0.13 | ||
| Q4 24 | $-13.10 | $-5.62 | ||
| Q3 24 | $-3.07 | $-3.06 | ||
| Q2 24 | $0.81 | $-0.58 | ||
| Q1 24 | $-5.58 | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $109.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $779.4M |
| Total Assets | $88.5M | $792.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | $109.1M | ||
| Q2 25 | $122.9M | $2.5M | ||
| Q1 25 | $137.9M | $4.2M | ||
| Q4 24 | $56.9M | $6.2M | ||
| Q3 24 | $74.9M | $2.1M | ||
| Q2 24 | $94.5M | $1.9M | ||
| Q1 24 | $112.7M | $1.9M |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | $779.4M | ||
| Q2 25 | $101.9M | $10.7M | ||
| Q1 25 | $116.4M | $19.6M | ||
| Q4 24 | $-29.0M | $23.3M | ||
| Q3 24 | $50.1M | $27.5M | ||
| Q2 24 | $67.2M | $5.4M | ||
| Q1 24 | $59.8M | $11.3M |
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | $792.6M | ||
| Q2 25 | $134.7M | $3.3M | ||
| Q1 25 | $150.7M | $5.0M | ||
| Q4 24 | $70.1M | $28.2M | ||
| Q3 24 | $88.4M | $2.6M | ||
| Q2 24 | $108.8M | $2.4M | ||
| Q1 24 | $127.9M | $2.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-14.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | — | ||
| Q3 25 | $-24.3M | $-14.0M | ||
| Q2 25 | $-15.5M | $-1.7M | ||
| Q1 25 | $-20.9M | $-1.6M | ||
| Q4 24 | $-18.4M | $-21.6M | ||
| Q3 24 | $-20.1M | $-13.2M | ||
| Q2 24 | $-19.5M | $-1.3M | ||
| Q1 24 | $-22.7M | $-1.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-21.6M | ||
| Q3 24 | — | $-13.4M | ||
| Q2 24 | — | $-1.3M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -10161.2% | ||
| Q3 24 | — | -1360.3% | ||
| Q2 24 | — | -1379.4% | ||
| Q1 24 | — | -844.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 11.3% | ||
| Q3 24 | — | 18.8% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 9.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
